Intraductal papillary mucinous neoplasms of the pancreas

A surgical perspective

George H. Sakorafas, Michael G. Sarr, C. J H van de Velde, George Peros

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas represent a relatively "new", but increasingly recognized entity. The emergence of this entity is due primarily to the widespread use of modern imaging methods, but also to a heightened awareness of physicians regarding this cystic neoplasm of the pancreas. No signs or symptoms are pathognomonic of IPMNs, but frequently, patients have a pancreatitis-like abdominal pain. Fully one-third of patients with IPMN are asymptomatic at the time of diagnosis. Cross-sectional imaging (ultrasonography, computed tomography, magnetic resonance cholangiopancreatography), endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography are the diagnostic and staging methods of choice in the evaluation of patients with IPMNs. IPMNs show a wide spectrum of histologic changes, ranging from adenoma to invasive neoplasm, even within the same neoplasm, suggesting a "field defect" predisposing major segments or even the entire ductal epithelium to the development of IPMN. Fine-needle aspiration/cytology and/or analysis of the cystic fluid may be useful diagnostic tools; however, these examinations are associated with high false-negative rates. Complete surgical resection is the therapeutic method of choice. The extent and type of pancreatectomy remain somewhat controversial but should be based on morphologic changes of the pancreas. Even the role of adjuvant therapy remains unclear; however, being "duct-derived" neoplasms of potential malignant character, some form of adjuvant chemo- or ratio-therapy seems indicated in the presence of invasive disease, despite a "curative" resection. In the absence of invasive disease, prognosis after R0 resection is highly favorable with recurrences of 5-10%. However, invasive IPMNs behave quite similar to ductal adenocarcinoma of the pancreas when analyzed stage-by-stage, with a slightly better prognosis; however, even after an R0 resection, recurrence is common.

Original languageEnglish (US)
Pages (from-to)155-178
Number of pages24
JournalSurgical Oncology
Volume14
Issue number4
DOIs
StatePublished - Dec 2005

Fingerprint

Pancreatic Neoplasms
Neoplasms
Pancreas
Magnetic Resonance Cholangiopancreatography
Recurrence
Endosonography
Pancreatectomy
Endoscopic Retrograde Cholangiopancreatography
Fine Needle Biopsy
Pancreatitis
Adenoma
Abdominal Pain
Signs and Symptoms
Cell Biology
Ultrasonography
Adenocarcinoma
Therapeutics
Epithelium
Tomography
Physicians

Keywords

  • Cystic neoplasms
  • Intraductal papillary mucinous tumors
  • IPMT
  • Pancreas

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Sakorafas, G. H., Sarr, M. G., van de Velde, C. J. H., & Peros, G. (2005). Intraductal papillary mucinous neoplasms of the pancreas: A surgical perspective. Surgical Oncology, 14(4), 155-178. https://doi.org/10.1016/j.suronc.2006.01.002

Intraductal papillary mucinous neoplasms of the pancreas : A surgical perspective. / Sakorafas, George H.; Sarr, Michael G.; van de Velde, C. J H; Peros, George.

In: Surgical Oncology, Vol. 14, No. 4, 12.2005, p. 155-178.

Research output: Contribution to journalArticle

Sakorafas, GH, Sarr, MG, van de Velde, CJH & Peros, G 2005, 'Intraductal papillary mucinous neoplasms of the pancreas: A surgical perspective', Surgical Oncology, vol. 14, no. 4, pp. 155-178. https://doi.org/10.1016/j.suronc.2006.01.002
Sakorafas, George H. ; Sarr, Michael G. ; van de Velde, C. J H ; Peros, George. / Intraductal papillary mucinous neoplasms of the pancreas : A surgical perspective. In: Surgical Oncology. 2005 ; Vol. 14, No. 4. pp. 155-178.
@article{28c1376b68cc4c88a6603462aa29bc6c,
title = "Intraductal papillary mucinous neoplasms of the pancreas: A surgical perspective",
abstract = "Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas represent a relatively {"}new{"}, but increasingly recognized entity. The emergence of this entity is due primarily to the widespread use of modern imaging methods, but also to a heightened awareness of physicians regarding this cystic neoplasm of the pancreas. No signs or symptoms are pathognomonic of IPMNs, but frequently, patients have a pancreatitis-like abdominal pain. Fully one-third of patients with IPMN are asymptomatic at the time of diagnosis. Cross-sectional imaging (ultrasonography, computed tomography, magnetic resonance cholangiopancreatography), endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography are the diagnostic and staging methods of choice in the evaluation of patients with IPMNs. IPMNs show a wide spectrum of histologic changes, ranging from adenoma to invasive neoplasm, even within the same neoplasm, suggesting a {"}field defect{"} predisposing major segments or even the entire ductal epithelium to the development of IPMN. Fine-needle aspiration/cytology and/or analysis of the cystic fluid may be useful diagnostic tools; however, these examinations are associated with high false-negative rates. Complete surgical resection is the therapeutic method of choice. The extent and type of pancreatectomy remain somewhat controversial but should be based on morphologic changes of the pancreas. Even the role of adjuvant therapy remains unclear; however, being {"}duct-derived{"} neoplasms of potential malignant character, some form of adjuvant chemo- or ratio-therapy seems indicated in the presence of invasive disease, despite a {"}curative{"} resection. In the absence of invasive disease, prognosis after R0 resection is highly favorable with recurrences of 5-10{\%}. However, invasive IPMNs behave quite similar to ductal adenocarcinoma of the pancreas when analyzed stage-by-stage, with a slightly better prognosis; however, even after an R0 resection, recurrence is common.",
keywords = "Cystic neoplasms, Intraductal papillary mucinous tumors, IPMT, Pancreas",
author = "Sakorafas, {George H.} and Sarr, {Michael G.} and {van de Velde}, {C. J H} and George Peros",
year = "2005",
month = "12",
doi = "10.1016/j.suronc.2006.01.002",
language = "English (US)",
volume = "14",
pages = "155--178",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Intraductal papillary mucinous neoplasms of the pancreas

T2 - A surgical perspective

AU - Sakorafas, George H.

AU - Sarr, Michael G.

AU - van de Velde, C. J H

AU - Peros, George

PY - 2005/12

Y1 - 2005/12

N2 - Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas represent a relatively "new", but increasingly recognized entity. The emergence of this entity is due primarily to the widespread use of modern imaging methods, but also to a heightened awareness of physicians regarding this cystic neoplasm of the pancreas. No signs or symptoms are pathognomonic of IPMNs, but frequently, patients have a pancreatitis-like abdominal pain. Fully one-third of patients with IPMN are asymptomatic at the time of diagnosis. Cross-sectional imaging (ultrasonography, computed tomography, magnetic resonance cholangiopancreatography), endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography are the diagnostic and staging methods of choice in the evaluation of patients with IPMNs. IPMNs show a wide spectrum of histologic changes, ranging from adenoma to invasive neoplasm, even within the same neoplasm, suggesting a "field defect" predisposing major segments or even the entire ductal epithelium to the development of IPMN. Fine-needle aspiration/cytology and/or analysis of the cystic fluid may be useful diagnostic tools; however, these examinations are associated with high false-negative rates. Complete surgical resection is the therapeutic method of choice. The extent and type of pancreatectomy remain somewhat controversial but should be based on morphologic changes of the pancreas. Even the role of adjuvant therapy remains unclear; however, being "duct-derived" neoplasms of potential malignant character, some form of adjuvant chemo- or ratio-therapy seems indicated in the presence of invasive disease, despite a "curative" resection. In the absence of invasive disease, prognosis after R0 resection is highly favorable with recurrences of 5-10%. However, invasive IPMNs behave quite similar to ductal adenocarcinoma of the pancreas when analyzed stage-by-stage, with a slightly better prognosis; however, even after an R0 resection, recurrence is common.

AB - Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas represent a relatively "new", but increasingly recognized entity. The emergence of this entity is due primarily to the widespread use of modern imaging methods, but also to a heightened awareness of physicians regarding this cystic neoplasm of the pancreas. No signs or symptoms are pathognomonic of IPMNs, but frequently, patients have a pancreatitis-like abdominal pain. Fully one-third of patients with IPMN are asymptomatic at the time of diagnosis. Cross-sectional imaging (ultrasonography, computed tomography, magnetic resonance cholangiopancreatography), endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography are the diagnostic and staging methods of choice in the evaluation of patients with IPMNs. IPMNs show a wide spectrum of histologic changes, ranging from adenoma to invasive neoplasm, even within the same neoplasm, suggesting a "field defect" predisposing major segments or even the entire ductal epithelium to the development of IPMN. Fine-needle aspiration/cytology and/or analysis of the cystic fluid may be useful diagnostic tools; however, these examinations are associated with high false-negative rates. Complete surgical resection is the therapeutic method of choice. The extent and type of pancreatectomy remain somewhat controversial but should be based on morphologic changes of the pancreas. Even the role of adjuvant therapy remains unclear; however, being "duct-derived" neoplasms of potential malignant character, some form of adjuvant chemo- or ratio-therapy seems indicated in the presence of invasive disease, despite a "curative" resection. In the absence of invasive disease, prognosis after R0 resection is highly favorable with recurrences of 5-10%. However, invasive IPMNs behave quite similar to ductal adenocarcinoma of the pancreas when analyzed stage-by-stage, with a slightly better prognosis; however, even after an R0 resection, recurrence is common.

KW - Cystic neoplasms

KW - Intraductal papillary mucinous tumors

KW - IPMT

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=33646024891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646024891&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2006.01.002

DO - 10.1016/j.suronc.2006.01.002

M3 - Article

VL - 14

SP - 155

EP - 178

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 4

ER -